Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Stock Forecast

Stock Price Forecast

The 15 analysts that cover Ultragenyx Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $85.2, which forecasts a 135.16% increase in the stock price over the next year. The lowest target is $34 and the highest is $140.

Price Target: $85.2 (+135.16%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$34	$85.2	$80	$140
Change	-6.16%	+135.16%	+120.81%	+286.42%

Analyst Ratings

The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	6	5	5	5	6	6
Buy	9	8	8	8	8	8
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	14	14	14	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gena Wang Barclays	Barclays	Buy Maintains $81 → $50	Buy	Maintains	$81 → $50	+38.01%	Nov 24, 2025
Yaron Werber TD Cowen	TD Cowen	Strong Buy Maintains $86 → $75	Strong Buy	Maintains	$86 → $75	+107.01%	Nov 5, 2025
Joon Lee Truist Securities	Truist Securities	Strong Buy Maintains $100 → $90	Strong Buy	Maintains	$100 → $90	+148.41%	Nov 5, 2025
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $80	Strong Buy	Reiterates	$80	+120.81%	Sep 9, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Reiterates $105	Buy	Reiterates	$105	+189.82%	Sep 5, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

667.17M

Increased by 19.09%

from 560.23M

Revenue Next Year

804.71M

Increased by 20.62%

from 667.17M

EPS This Year

-5.87

from -6.29

EPS Next Year

-4.19

from -5.87

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	271.03M	351.41M	363.33M	434.25M	560.23M	667.17M	804.71M
Revenue Growth	161.32%	29.66%	3.39%	19.52%	29.01%	19.09%	20.62%
EPS	-3.07	-6.70	-10.12	-8.25	-6.29	-5.87	-4.19
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	23	22

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	696.4M	931.0M
Avg	667.2M	804.7M
Low	618.4M	661.9M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	24.3%	39.6%
Avg	19.1%	20.6%
Low	10.4%	-0.8%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-4.71	-1.11
Avg	-5.87	-4.19
Low	-7.60	-6.56

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.